Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given an average rating of “Buy” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.83.

IMNM has been the subject of a number of recent analyst reports. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Piper Sandler dropped their target price on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Finally, Stephens began coverage on Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company.

Insider Activity

In related news, insider Robert Lechleider purchased 15,805 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the completion of the acquisition, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Clay B. Siegall acquired 66,057 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.54 per share, with a total value of $630,183.78. Following the transaction, the chief executive officer now owns 485,693 shares in the company, valued at $4,633,511.22. The trade was a 15.74 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 102,862 shares of company stock worth $978,045. 8.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IMNM. Arizona State Retirement System boosted its stake in Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after buying an additional 918 shares during the last quarter. Clear Creek Financial Management LLC boosted its stake in shares of Immunome by 18.2% during the 2nd quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock valued at $317,000 after buying an additional 4,035 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the last quarter. Cerity Partners LLC boosted its stake in Immunome by 10.5% in the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock valued at $776,000 after acquiring an additional 5,043 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of Immunome during the second quarter valued at approximately $81,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Stock Performance

NASDAQ IMNM opened at $10.97 on Friday. The company’s 50-day simple moving average is $12.14 and its two-hundred day simple moving average is $13.35. Immunome has a one year low of $8.15 and a one year high of $30.96. The company has a market capitalization of $684.71 million, a price-to-earnings ratio of -1.35 and a beta of 1.83.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.